Ligand-targeted therapeutics in anticancer therapy

被引：1357

作者：

Allen, TM ^{[1
]}

机构：

[1] Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada

来源：

NATURE REVIEWS CANCER | 2002年 / 2卷 / 10期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1038/nrc903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens, This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted therapeutics.

引用

页码：750 / 763

页数：14

共 122 条

[1]

Adams GP, 2001, CANCER RES, V61, P4750

[2]

Therapeutic opportunities for targeted liposomal drug delivery [J].

Allen, TM ;

Moase, EH .

ADVANCED DRUG DELIVERY REVIEWS, 1996, 21 (02) :117-133

[3]

Adventures in targeting [J].

Allen, TM ;

Sapra, P ;

Moase, E ;

Moreira, J ;

Iden, D .

JOURNAL OF LIPOSOME RESEARCH, 2002, 12 (1-2) :5-12

[4]

Allen TM, 1998, MEDICAL APPLICATIONS OF LIPOSOMES, P297, DOI 10.1016/B978-044482917-7/50018-1

[5]

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome [J].

Baluna, R ;

Rizo, J ;

Gordon, BE ;

Ghetie, V ;

Vitetta, ES .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3957-3962

[6]

The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro:: Insights into toxin-mediated vascular damage [J].

Baluna, R ;

Coleman, E ;

Jones, C ;

Ghetie, V ;

Vitetta, ES .

EXPERIMENTAL CELL RESEARCH, 2000, 258 (02) :417-424

[7]

Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue [J].

Banerjee, RK ;

van Osdol, WW ;

Bungay, PM ;

Sung, C ;

Dedrick, RL .

JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :193-202

[8]

Pretargeting with the Affinity Enhancement System for radioimmunotherapy [J].

Barbet, J ;

Kraeber-Bodéré, F ;

Vuillez, JP ;

Gautherot, E ;

Rouvier, R ;

Chatal, JF .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (03) :153-166

[9]

Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J].

Baselga, J .

ONCOLOGY, 2001, 61 :14-21

[10]

RETRACTED: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer -: Results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14 (Retracted article. See vol. 121, pg. 2290, 2015) [J].

Behr, TM ;

Liersch, T ;

Greiner-Bechert, L ;

Griesinger, F ;

Béhé, M ;

Markus, PM ;

Gratz, S ;

Angerstein, C ;

Brittinger, G ;

Becker, H ;

Goldenberg, DM ;

Becker, W .

CANCER, 2002, 94 (04) :1373-1381

← 1 2 3 4 5 6 7 8 9 10 →